% | $
Quotes you view appear here for quick access.

Gilead Sciences Inc. Message Board

  • citamar citamar Jan 9, 2002 8:28 AM Flag

    Goldman Upgrades- Target $80

    Just what we needed this morning, an upgrade by Goldman. Put GILD on recommended list. Can anyone say $70 by the end of the week. This stock is incredible!

    7:51AM Gilead Sciences (GILD) 63.84: Goldman Sachs upgrades to RECOMMENDED LIST from Mkt Outperform, based valuation and strong 2002 sales prospects, solid pipeline, and nearing profitability; key growth driver will be Viread. Firm maintains $75-$80 price target.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Basically since John Martin all but said that Tenofovir sales won't be a disaster, that's enough to get the stock up a few bucks.

      Tells you how much event risk on a Tenofovir sales dissapointment the market was pricing in.

      The other risk of course is if GILD takes over another biotech firm with a (relatively) large market cap. I'd say anything over a $600M acquisition would affect GILD's stock price.

      Implied volatility is low, this still suggests that GILD is going to be trading in the 60-70 dollar band. Selling one-month at the money covered when/if the common stock hits 70-71 bucks might be the viable strategy. We'll see how it unfolds.

89.44+2.08(+2.38%)Feb 12 4:00 PMEST